Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics Gets NY State Clinical Lab Permit

NEW YORK (GenomeWeb News) – Good Start Genetics today said that it has received a clinical lab permit from the New York State Department of Health, enabling the firm to offer its GoodStart Select carrier screening tests to in vitro fertilization and other reproductive health physicians in the state.

The Cambridge, Mass.-based firm offers a next-generation sequencing-based carrier screening test. The service provides testing for all 23 diseases recommended by major medical societies and detects common disease-causing mutations and rare pathogenic mutations that older, traditional genotyping-based technologies cannot detect, the firm has said.

Good Start said that with the license from NY State its lab becomes the first to offer extensively validated NGS-based carrier screening in New York.

"Obtaining the New York state license is an important achievement for Good Start, and we're very proud our operation has passed the rigorous New York inspection and approval process," Don Hardison, president and CEO of Good Start Genetics, said in a statement.

The firm noted that since its launch of GoodStart Select in April 2012, its lab has processed more than 100,000 tests.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.